Apollo Cancer Centres launches Early Detection and Diagnosis for Endometrial and Ovarian Cancers

Reinforcing its commitment to preventive oncology for women, Apollo Cancer Centre (ACC), and Apollo Proton Cancer Centre (APCC), launched  End-O Check, a comprehensive early detection program targeting women. The initiative is designed to detect two of the most prevalent gynaecologic cancers—endometrial and ovarian - at an early and more treatable stage.

As part of the launch of End-O Check, a Panel Discussion was organised by Apollo Cancer Centre and Apollo Proton Cancer Centre to raise awareness on ovarian and endometrial cancers, focusing on the importance of early detection, educating women, and addressing myths that delay timely care. Dr. Ajit Pai, Senior Consultant - Surgical Oncology, ACC-Teynampet, Dr. Venkat P, Senior Consultant - Surgical Oncology, ACC-Teynampet, and Dr. Kumar Gubbala, Consultant – Gynaecological Oncology, APCC, Dr. Madhu Priya, Senior Consultant - Surgical Oncology, ACC-Vanagaram,Dr. Priya Kapoor, Consultant, Surgical Oncology, ACC-Teynampet, were part of the panel discussion, which was moderated by Dr. Ayyappan, Senior Consultant - Surgical Oncology, ACC-Teynampet.

Ovarian cancer, often referred to as the “silent killer,” affects women between 55 and 64 years of age, with the average diagnosis occurring at 63. When caught early, the five-year survival rate exceeds 90%.

In India, the total cancer cases are projected to grow to 1.57 million by 2025, with ovarian and uterine cancers continuing to report among the top five cancers affecting women. The age-standardized incidence rates are estimated at 4.6 per 100,000 for ovarian cancers and 2.5 per 100,000 for corpus uterine cancers^2.Contributing factors include shifts in reproductive patterns, urban lifestyles, and a rise in metabolic conditions,highlighting the urgent need for targeted  detection in high-risk populations.

While endometrial cancer often presents with symptoms such as unexpected bleeding or abnormal discharge, many women fail to report these signs early, leading to delayed diagnosis and poorer outcomes. End-OCheck is designed with a focus onearly detection in high-risk populations, symptom awareness, and timely intervention, empowering women to take proactive steps for their gynaecologic health.

Speaking at the launch, Mr. Dinesh Madhavan, President, Group Oncology & International, Apollo Hospitals Enterprise Ltd, said, "Early detection remains our most powerful ally in improving survival and quality of life in cancer care. End-O Check is a proactive step in shifting the narrative from treatment todetection and early diagnosis , enabling timely detection, and precision treatment by cancer managmenet teams “ .

Mr Karan Puri, Chief Executive Officer, Apollo Cancer Centres & Apollo Proton Cancer Centre, Chennai, added, "With End-O Check, we are further extending our commitment to preventive oncology. This program goes beyond clinical protocols, it is about creating awareness, encouraging women to prioritize their health, and ensuring access to comprehensive detection solutions. Early detection not only saves lives but also allows us to provide more effective, less invasive treatments."